IP Rights

Company

Board
Management

IP Rights

Pharma Holdings IP Rights

Pharma Holdings has secured broadly defined rights to our new class of cationic antimicrobial peptides– harnessing the essence of naturally occurring host defense molecules and designing around the potential instability challenges linked with antimicrobial peptides. We are also actively exploring new patent applications to prolong and expand our IPR. Two patents are already granted, and three new IP filings will reach the PCT filing stage during 2022.